Considering the crucial roles of the four chemokines (CXCL9, CXCL10, CXCL11, and CCL5) and the three pivotal immune cells (Macrophages M1, CD 4, and CD8 T cells) in tumor immunity, we established a criterion predicting the validity of ICB therapy through neural network, in which the AUC in training and test sets achieved 100% and 74%, respectively. This evidence concerns the gene CD8A and neoplasm.